Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer
United States30 participantsStarted 2026-06
Plain-language summary
To evaluate the safety, tolerability, and preliminary efficacy of moderately hypofractionated (15-fraction) MR-guided adaptive pelvic IMRT in patients with endometrial cancer.
Who can participate
Age range
18 Years – 90 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
. Indication for adjuvant pelvic radiotherapy (± vaginal brachytherapy) for HIR defined by the ASTRO guidelines and GOG-99(7, 9) :
. Age
. High-grade histology (grade 2-3)
. Depth of myometrial invasion
. LVSI
. Positive pelvic nodes
. Cervical stromal invasion
Exclusion criteria
. Prior pelvic radiotherapy.
. Contraindication to pelvic radiotherapy (e.g., active connective tissue disorder or inflammatory bowel disease).
. Presence of a hip prosthesis that would compromise treatment planning or delivery.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is specifically measuring serious side effects to the bowel and bladder — what does a Grade 2 or higher gastrointestinal or genitourinary toxicity actually look and feel like, and how would it be managed if it happened to me?
2Since this trial uses MR-guided radiation that adapts daily to my anatomy, how does that approach differ from the standard radiation I might receive outside of this study, and what are the practical trade-offs in terms of appointment time and frequency?
3The trial is listed as 'not yet recruiting' — given my specific diagnosis and timeline for starting adjuvant treatment, is it realistic to wait for this study to open, or would starting standard care now be the safer path?
4This trial doesn't have a traditional phase assigned to it, which means the primary focus seems to be on understanding side effects rather than proving survival benefit — does that change how you'd weigh it against established adjuvant radiation options for my stage of endometrial cancer?
5MR-guided radiation requires specialized equipment — how far would I need to travel for each treatment session, and given that radiation is typically delivered over multiple weeks, is that logistically feasible for my situation?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence of Acute Grade ≥2 Gastrointestinal and Genitourinary Toxicity
Timeframe: Within 90 days after completion of treatment
Trial details
NCT IDNCT07643012
SponsorRutgers, The State University of New Jersey